Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.
Fiche publication
Date publication
janvier 2022
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno
Tous les auteurs :
Squara PA, Luu VP, Pérol D, Coudert B, Machuron V, Bachot C, Samelson L, Florentin V, Pinguet JM, Ben Hadj Yahia B
Lien Pubmed
Résumé
This article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France.
Mots clés
Antineoplastic Agents, therapeutic use, Breast Neoplasms, drug therapy, Carcinoma, Non-Small-Cell Lung, drug therapy, Drug Costs, Female, France, Humans, Lung Neoplasms, drug therapy, Retrospective Studies, Trastuzumab, therapeutic use
Référence
PLoS One. 2022 ;17(4):e0267242